Ling-I Chien

Ling-I Chien

Auto-generated profile, based on publicly available information

Ling-I Chien

Department of Nursing, Taipei Veterans General Hospital, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2025 in Journal of Chest Surgery
Verified
Journal Article
Open access
CLChia Liu
Chia Liu
YYYi-Chen Yeh
Yi-Chen Yeh
LCLing-I Chien
Ling-I Chien
CHChien-Sheng Huang
Chien-Sheng Huang
HHHan-Shui Hsu
Han-Shui Hsu
PHPo-Kuei Hsu
Po-Kuei Hsu
The CheckMate 577 trial demonstrated that adjuvant nivolumab improves disease-free survival in patients with resected esophageal cancer following neoadjuvant chemoradiotherapy. This study aimed to evaluate real-world outcomes associated with adjuvant immunotherapy. Patients with esophageal cancer and residual pathological disease who underwent neoadjuvant therapy followed by surgical resection between January 2019 and February 2024 were retrospectively analyzed. Participants were grouped by adjuvant treatment received: no adjuvant therapy, adjuvant immunotherapy (AI), or adjuvant chemotherapy (AC). Primary outcomes included overall survival (OS) and recurrence-free survival (RFS). Subgroup analyses were performed for patients meeting CheckMate 577 eligibility criteria and those with pathological node-positive (ypN+) status. The study included 127 patients (mean age: 60 years; male: 86%): 23 received AI, 36 AC, and 68 received no adjuvant therapy. There were no significant differences in OS between AI and AC groups (median OS [mOS]: 34 months vs. 34 months; p=0.81), nor in RFS (median RFS [mRFS]: 15 months vs. 16 months; p=0.94). In the CheckMate 577-eligible subgroup (n=68), OS and RFS were similar between AI and AC groups (mOS: 25 months vs. 47 months; p=0.16; mRFS: 19 months vs. 20 months; p=0.74). Likewise, among ypN+ patients (n=54), no significant differences in OS or RFS were noted between AI and AC (mOS: 34 months vs. 31 months; p=0.74; mRFS: 9.5 months vs. 14 months; p=0.89). AI did not demonstrate a significant survival advantage compared to AC, even in patients meeting CheckMate 577 criteria or those with ypN+ status. Identifying the optimal adjuvant treatment for esophageal cancer remains a challenging and evolving issue.

17 December 2025 in Journal of Chest Surgery
Verified
Journal Article
Open access
PDF file
PTPing-Chung Tsai
Ping-Chung Tsai
CLChia Liu
Chia Liu
LCLing-I Chien
Ling-I Chien
ETEn-Kuei Tang
En-Kuei Tang
CHChien-Sheng Huang
Chien-Sheng Huang
PHPo-Kuei Hsu
Po-Kuei Hsu
Ping-Chung Tsai, M.D., Chia Liu, M.D., Ling-I Chien, M.S., En-Kuei Tang, M.D., Chien-Sheng Huang, M.D., Ph.D., Chih-Cheng Hsieh, M.D., Ph.D., Han-Shui Hsu, M.D., Ph.D., Po-Kuei Hsu, M.D., Ph.D.. J Chest Surg -0001;0:. https://doi.org/10.5090/jcs.25.111

23 September 2025 in Journal of Chest Surgery
Verified
Journal Article
Open access
PDF file
CLChia Liu
Chia Liu
LCLing-I Chien
Ling-I Chien
YHYi-Ping Hung
Yi-Ping Hung
TLTzu-Yu Lai
Tzu-Yu Lai
CHChien-Sheng Huang
Chien-Sheng Huang
PHPo-Kuei Hsu
Po-Kuei Hsu
Chia Liu, M.D., Ling-I Chien, B.S., Yi-Ping Hung, M.D., Ph.D., Tzu-Yu Lai, M.D., Ph.D., Chien-Sheng Huang, M.D., Ph.D., Han-Shui Hsu, M.D., Ph.D., Ming-Huang Chen, M.D., Ph.D., Pin-I Huang, M.D., Ph.D., Po-Kuei Hsu, M.D., Ph.D.. J Chest Surg -0001;0:. https://doi.org/10.5090/jcs.25.040

20 March 2026 in Journal of Chest Surgery
Verified
Journal Article
Open access
PDF file
YTYing-Che Ting
Ying-Che Ting
LCLing-I Chien
Ling-I Chien
CLChia Liu
Chia Liu
YLYi-Ying Lee
Yi-Ying Lee
CHChien-Sheng Huang
Chien-Sheng Huang
PHPo-Kuei Hsu
Po-Kuei Hsu
Ying-Che Ting, M.D., Ling-I Chien, B.S., Chia Liu, M.D., Yi-Ying Lee, M.D., Chien-Sheng Huang, M.D., Yu-Chung Wu, M.D., Po-Kuei Hsu, M.D., Ph.D.. J Chest Surg -0001;0:. https://doi.org/10.5090/jcs.25.108